HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Technetium-99m-sestamibi uptake by recurrent Hurthle cell carcinoma of the thyroid.

Abstract
Technetium-99m-sestamibi has been reported to localize in various tumors. Scintigraphic results for a patient with recurrent Hurthle cell carcinoma of the thyroid whose tumor was imaged with both 99mTc-sestamibi and 201TI, but not with 131I, are presented.
AuthorsH R Balon, D Fink-BennetT, S S Stoffer
JournalJournal of nuclear medicine : official publication, Society of Nuclear Medicine (J Nucl Med) Vol. 33 Issue 7 Pg. 1393-5 (Jul 1992) ISSN: 0161-5505 [Print] United States
PMID1535374 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Iodine Radioisotopes
  • Organotechnetium Compounds
  • Thallium Radioisotopes
  • Technetium Tc 99m Sestamibi
Topics
  • Aged
  • Carcinoma (diagnostic imaging, metabolism)
  • Humans
  • Iodine Radioisotopes
  • Male
  • Neoplasm Recurrence, Local (diagnostic imaging, metabolism)
  • Organotechnetium Compounds (pharmacokinetics)
  • Radionuclide Imaging
  • Technetium Tc 99m Sestamibi
  • Thallium Radioisotopes
  • Thyroid Neoplasms (diagnostic imaging, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: